Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed · Phase 3

Conditions studied: Kidney Failure, Chronic

In brief

The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor.

Key facts

Study ID

NCT00275509

Run by

Johns Hopkins University

People needed

56

Starts

2007-01-01

Expected to finish

2010-06-01

Last updated by the study team

2018-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult (18 years or older)
• End-stage renal disease
• Identified to have positive lymphocytotoxic crossmatch or flow cytometric crossmatch with live donor

You may not qualify if…

• Deceased donor recipients
• Pregnancy
• Active infection
• History of cancer within the past two years (with the exception of non-melanomatous skin cancer)
• History of heparin induced thrombocytopenia
• Medical contraindications to transplant procedure

Where it is running

• The Johns Hopkins University, School of Medicine — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.